Medicine
fromArs Technica
1 day agoBad cholesterol slashed 62% by single dose of gene-editing drug in small trial
VERVE-102 uses base editing to permanently disrupt PCSK9, reducing LDL in a dose-dependent manner with larger doses producing greater gene knockout and LDL lowering.